Ten-year outcomes of high-dose, intensity-modulated radiotherapy for XXXX .

@entity1 @entity137 @entity263 @entity5 @entity1486
BACKGROUND: The authors investigated long-term @entity5 control and @entity137 outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in @entity1 who had clinically @entity263 . METHODS: Between April 1996 and January 1998, 170 @entity1 received 81 gray (Gy) using a 5-field IMRT technique. @entity1 were classified according to the National @entity5 Network-defined risk groups. @entity137 data were scored according to the Common Terminology Criteria for Adverse Events Version 3.0. Freedom from biochemical relapse, distant metastases, and cause-specific survival outcomes were calculated. The median follow-up was 99 months. RESULTS: The 10-year actuarial @entity1486 relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group; the 10-year distant metastases-free rates were 100%, 94%, and 90%, respectively; and the 10-year cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary @entity137 was 11% and 5%, respectively; and the 10-year likelihood of developing grade 2 and 3 late gastrointestinal @entity137 was 2% and 1%, respectively. No grade 4 @entity137 were observed. CONCLUSIONS: To the authors' knowledge, this report represents the longest followed cohort of @entity1 who received high-dose radiation levels of 81 Gy using IMRT for @entity263 . The findings indicated that high-dose IMRT is well tolerated and is associated with excellent long-term @entity5 -control outcomes in @entity1 with @entity263 .
